Regulators Call for More Harmonization On Ultra-Rare ATMPs
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
You may also be interested in...
The norms on securing market access are being rewritten for cell and gene therapies.
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.